The RemeOs alloy is said to be a crucial component of Bioretec’s trauma screws. Credit: Roman Zaiets/Shutterstock.com.

The US Patent Office has allowed a patent for Bioretec’s RemeOs magnesium alloy composition and will grant and publish it upon company confirmation.

The patent encompasses the use of the RemeOs magnesium-calcium-zinc alloy in the manufacturing of orthopaedic implants or parts thereof for all patient demographics.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This alloy is a crucial component of Bioretec’s trauma screws and is expected to be incorporated into future product offerings.

The company is also advancing its efforts to secure international protection for the RemeOs alloy by initiating a PCT [Patent Cooperation Treaty] application that would extend its patent coverage beyond the US.

Bioretec CEO Timo Lehtonen said: “The allowance of this patent for RemeOs biodegradable metal composition in the US, which is our main target market, is an integral part of our IPR strategy and protection of RemeOs technology.”

The company is pioneering the development of the RemeOs product line, which makes use of magnesium alloy and hybrid composite to introduce a new era of biodegradable materials aimed at enhancing surgical outcomes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These RemeOs implants are designed to be gradually absorbed and replaced by bone, eliminating the necessity for removal surgery and expediting fracture healing.

The company’s first RemeOs product received market authorisation in the US in March last year. The CE mark in Europe is anticipated by the second quarter of 2024.

In 2022, Bioretec submitted an application seeking a CE mark for its bioresorbable RemeOs trauma screw to commercialise in the EU. The magnesium alloy trauma screw is part of the company’s new RemeOs product family.